Multidetector-row computed tomography made changes in bone microarchitecture visible among bisphosphonate-treated patients with glucocorticoid-induced osteoporosis.
Post-menopausal women taking less than the standard 5 mg dose of zoledronate did just as well on bone density and turnover measures, according to a randomized trial.
New in the nonspecialty journals: A new option for patients with autoimmune disease and HCV infection. The value of combined therapy for osteoporosis. Prognosis predictors for chronic pain, a new opioid adverse effect, and more ...
New in the major nonspecialist journals: Bevra Hahn MD tells how she uses belimumab in lupus, a case report of an adverse effect of rituximab, a new proposal for identifying osteoporosis.
A small randomized trial from Italy found that while zoledronic acid (Reclast) slows bone loss in osteoporosis, it may also slow bone formation. Perhaps combination therapy is required.
Test your skills about the diagnosis and treatment of osteoporosis in this brief quiz offered by Nancy Lane MD.
Women with higher uric acid levels around and after menopause show less bone loss. What could this mean?
In response to a study published in the journal Heart that suggested a link between calcium supplementation and an increased risk of heart attack, the National Osteoporosis Foundation stated that the findings are inconclusive and that more research is needed to better understand the potential relationship between calcium supplements and heart attack risk.
Recent years have witnessed tremendous advances in the field of orthopedic surgery, particularly in total joint arthroplasty.
The first generic versions of Boniva (ibandronate) tablets, a once-monthly product for managing or preventing osteoporosis in postmenopausal women, have received FDA approval.